CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
一例 60 多岁伴免疫缺陷与肝炎的男性
英文原题：A man in his 60s with immunodeficiency and hepatitis.
查看英文原题
A man in his 60s with immunodeficiency and hepatitis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
免疫功能受损患者数量不断增加，意味着更多患者面临发生慢性戊型肝炎的风险。
中文摘要
**背景：**肝酶升高的主要原因包括毒性、感染、肿瘤和自身免疫性疾病。免疫功能低下患者可导致肝炎的感染病原体范围更广，且免疫反应受抑，使诊断更具挑战。 **病例介绍：**一名60多岁男性曾因多发性骨髓瘤接受CAR-T 治疗。 **解读：**免疫功能低下患者数量增加，意味着更多患者面临慢性戊型肝炎风险。对此类患者，血清学检测可能不可靠，戊型肝炎病毒（HEV）RNA核酸检测应作为主要诊断方法。挪威也可感染HEV，而戊型肝炎仍是一种诊断不足的感染。
展开英文摘要原文
BACKGROUND: Major causes of elevated liver enzymes are toxic, infectious, neoplastic and autoimmune disease. In immunocompromised patients, the spectrum of infectious pathogens causing hepatitis is broader and the immune response is blunted, making diagnosis more challenging. CASE PRESENTATION: A man in his sixties had received CAR-T therapy for multiple myeloma. INTERPRETATION: The increasing number of immunocompromised patients means that more patients are at risk of developing chronic hepatitis E. Serologic tests may be unreliable for this patient population, and nucleic acid testing for HEV RNA should be the primary diagnostic approach. HEV can be contracted in Norway, and hepatitis E is an underdiagnosed infection.
论文信息
- 作者
- Hvitmyhr C、Enga KF、Øverbø J、Midgard H、Reikvam DH
- 第一作者单位
- Medisinsk avdeling, Ringerike sykehus, Vestre Viken.
- 通讯作者单位
- Infeksjonsmedisinsk avdeling, Oslo universitetssykehus, Ullevål, og, Institutt for klinisk medisin, Universitetet i Oslo.Norway
- 文献类型
- 病例报告
- 期刊
- Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke2026 Feb 10
- 原文标识
- PubMed 41670322 · DOI 10.4045/tidsskr.25.0487